Biora Therapeutics (BIOR) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free BIOR Stock Alerts $0.61 +0.02 (+2.88%) (As of 02:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20, 2024 | globenewswire.comBiora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024May 20, 2024 | americanbankingnews.comHC Wainwright Comments on Biora Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:BIOR)May 18, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Biora Therapeutics (NASDAQ:BIOR)May 16, 2024 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16, 2024 | finance.yahoo.comBIOR: BT-600 Data in JuneMay 16, 2024 | msn.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comBiora Therapeutics Inc (BIOR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 15, 2024 | msn.comBiora Therapeutics GAAP EPS of -$0.14 beats by $0.31, revenue of $0.54MMay 15, 2024 | finance.yahoo.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comBiora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate UpdateMay 6, 2024 | globenewswire.comBiora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024April 30, 2024 | globenewswire.comBiora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600April 18, 2024 | msn.comBiora Therapeutics (BIOR) Price Target Decreased by 62.95% to 10.51April 15, 2024 | nasdaq.comBiora Therapeutics, Inc. Common Stock (BIOR)April 10, 2024 | stockhouse.comBiora Therapeutics Announces New Patent Covering its BioJet(TM) Liquid Jet Delivery TechnologyApril 9, 2024 | markets.businessinsider.comBiora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery InnovationsApril 8, 2024 | globenewswire.comBiora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery TechnologyApril 4, 2024 | markets.businessinsider.comBiora Therapeutics Gets Positive Interim Data From Clinical Trial Of BT-600 With NaviCap; Stock DownApril 4, 2024 | globenewswire.comBiora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform DevelopmentApril 3, 2024 | globenewswire.comBiora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 2, 2024 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | finance.yahoo.comBiora Therapeutics Full Year 2023 Earnings: Beats ExpectationsApril 1, 2024 | msn.comPrecision Biosciences, Mesoblast, Pulse Biosciences among healthcare moversApril 1, 2024 | marketwatch.comBiora Therapeutics Shares Drop 26% After Pricing of Direct OfferingApril 1, 2024 | globenewswire.comBiora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMarch 28, 2024 | seekingalpha.comBiora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBIOR: Negotiations AcceleratingMarch 27, 2024 | finance.yahoo.comBiora Therapeutics, Inc. (NASDAQ:BIOR) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finanznachrichten.deBiora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 27, 2024 | benzinga.comBiora Therapeutics: Q4 Earnings InsightsMarch 27, 2024 | finance.yahoo.comQ4 2023 Biora Therapeutics Inc Earnings CallMarch 26, 2024 | globenewswire.comBiora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsMarch 25, 2024 | markets.businessinsider.comHere's what Wall Street expects from Biora Therapeutics's earningsMarch 18, 2024 | globenewswire.comBiora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateMarch 11, 2024 | msn.comBiora Therapeutics announces new capital investmentMarch 11, 2024 | globenewswire.comBiora Therapeutics Further Reduces Net Debt and Monetizes Legacy AssetMarch 7, 2024 | finance.yahoo.comBIOR Jul 2024 4.000 callMarch 7, 2024 | finance.yahoo.comBIOR Apr 2024 2.500 putMarch 7, 2024 | finance.yahoo.comBIOR Apr 2024 1.000 putMarch 7, 2024 | finance.yahoo.comBIOR Oct 2024 2.000 callMarch 3, 2024 | ca.finance.yahoo.comBIOR Oct 2024 4.000 putMarch 1, 2024 | morningstar.comBiora Therapeutics Inc Ordinary Shares BIORFebruary 26, 2024 | finance.yahoo.comBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600February 26, 2024 | globenewswire.comBiora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600February 21, 2024 | markets.businessinsider.comHere's what Wall Street expects from iRhythm Technologies's earnings reportFebruary 17, 2024 | finance.yahoo.comBIOR Mar 2024 1.000 callFebruary 8, 2024 | finance.yahoo.comBiora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease SymposiumJanuary 22, 2024 | finance.yahoo.comBiora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.January 8, 2024 | finance.yahoo.comBiora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600 Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Three basic steps to building the Ultimate Dividend Portfolio. (Ad)There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will. Click here to get them (for Free). BIOR Media Mentions By Week BIOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIOR News Sentiment▼1.150.92▲Average Medical News Sentiment BIOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIOR Articles This Week▼32▲BIOR Articles Average Week Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NanoViricides News Today Lisata Therapeutics News Today Oncternal Therapeutics News Today Unity Biotechnology News Today BriaCell Therapeutics News Today Bullfrog AI News Today Aprea Therapeutics News Today Cumberland Pharmaceuticals News Today Enlivex Therapeutics News Today Iterum Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIOR) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesThe only AI company to buyPorter & CompanyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestWARNING about the death of the U.S. dollar…Colonial MetalsBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsIs Artificial Intelligence the Biggest Bubble in History?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.